“These three blue chip stocks lost investors over 60%. The names will surprise you.” There is a belief that runs deep in the Indian retail investor’s mind: blue chip stocks don’t really hurt you. You hear it at family dinners. You read it in introductory investing guides. You believe it when your broker says, “Sir,…
Forget SIPs: The Wealthy Investor’s Guide to Using Debt for Cash-Flow Generating Assets
We’ve all heard the golden rule of investing: Start a small SIP (Systematic Investment Plan) today, and compounding will make you rich tomorrow. This advice is everywhere—from banks and mutual fund ads to every personal finance influencer. It is a powerful tool for building discipline and wealth from a small base. But here is the…
IndiGo’s December Meltdown: What Went Wrong and the Big Lessons for India’s Aviation Sector
In early December 2025, India’s largest airline, IndiGo, faced its worst operational crisis, cancelling over 1,000 flights in a single day and grounding nearly all departures from major hubs like Delhi, Mumbai, Bengaluru, and Hyderabad. Terminals were packed with stranded passengers, last-minute fares on other airlines skyrocketed, and the government had to step in to…
10 Key Insights from the Nikhil Kamath & Elon Musk Podcast
Here are 10 key insights from Nikhil Kamath & Elon Musk Podcast – original link to the podcast. 1. Work Becomes Optional Elon Musk predicts that within 10 to 20 years, working will become optional due to the rapid advancements in AI and robotics. This transformation is described as a “supersonic tsunami,” the most radical…
Stock Split & Bonus 2025: Impact on Price, Examples & Analysis
Stock splits and bonus issues are two of the most popular corporate actions in Indian markets, often generating excitement among retail investors. But what exactly happens to the share price when these events are announced? Do they create real value, or is it just a psychological boost? Let’s explore the facts, figures, and real-world impact…
Eli Lilly’s $1 Trillion Moment: How Mounjaro Is Reshaping the GLP-1 Market in India and the US
If you’d told anyone a decade ago that a 150-year-old insulin maker from Indiana would join the $1 trillion club alongside Apple and Microsoft, they’d have laughed. Yet that’s exactly what Eli Lilly just did. On the back of its breakthrough weight-loss and diabetes drugs Mounjaro (tirzepatide) and Zepbound, Lilly has become the first pharma…